Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kirolos Adly

Psychiatry Biloxi, MS Doctor of Osteopathy

NPI 1891360384 CMS profile 11431320

189 Walmart Ln Ste B, Biloxi, MS 39531

Open in the dashboard

General payments

$6,096

166 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirolos Adly of Biloxi, MS is reported in the CMS Open Payments database as having received $6,096 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,555 31
2024 General $2,368 70
2023 General $1,527 41
2022 General $646 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirolos Adly
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kirolos Adly were reported at $1,555. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kirolos Adly Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $646 $153 $50–$590 $149
2023 $1,527 $170 $56–$651 $160
2024 $2,368 $179 $57–$673 $164
2025 $1,555 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Teva Pharmaceuticals USA, Inc. $1,241 38 payments
  2. Alkermes, Inc. $876 17 payments
  3. Otsuka America Pharmaceutical, Inc. $805 19 payments
  4. Neurocrine Biosciences, Inc. $720 22 payments
  5. Lundbeck LLC $415 18 payments
  6. Janssen Pharmaceuticals, Inc $389 10 payments
  7. Vanda Pharmaceuticals Inc. $339 6 payments
  8. E.R. Squibb & Sons, L.L.C. $331 9 payments
  9. Avanir Pharmaceuticals, Inc. $223 9 payments
  10. Axsome Therapeutics, Inc. $223 2 payments
  11. Other $534 16 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,096 166 payments
Products named General payments · program years 2022–2025
  1. INGREZZA $720 22 payments
  2. ABILIFY MAINTENA $708 25 payments
  3. LYBALVI $650 15 payments
  4. UZEDY $530 21 payments
  5. ARISTADA Cns $509 14 payments
  6. ARISTADA Cns $509 14 payments
  7. ARISTADA Cns $509 14 payments
  8. ARISTADA Cns $509 14 payments
  9. Austedo XR $480 11 payments
  10. ABILIFY ASIMTUFII $420 13 payments
  11. Other $4,170 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

619

Median for Psychiatry: 574

Drug cost

$292,959

Median for Psychiatry: $27,624

Branded share of claims

16.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 19 $150,260
Abilify Maintena Aripiprazole Brand 22 $65,855
Uzedy Risperidone Brand 17 $62,952
Trintellix Vortioxetine Hydrobromide Brand 11 $6,531
Haloperidol Decanoate Generic 14 $768
Aripiprazole Generic 33 $664
Quetiapine Fumarate Generic 27 $560
Ziprasidone Hcl Generic 13 $536
Trazodone Hcl Generic 82 $530
Prazosin Hcl Generic 39 $469

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$495 19 —
Austedo XR
$323 — —
REXULTI
$304 — —
UZEDY
$217 17 —
ARISTADA
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record